Summit Therapeutics Inc.

0.8000-0.0900-10.11%Vol 454.47K1Y Perf -82.48%
Nov 30th, 2022 16:00 DELAYED
BID0.7555 ASK0.8000
Open0.8900 Previous Close0.8900
Pre-Market- After-Market0.80
 - -  - -%
Target Price
4.00 
Analyst Rating
— 0.00
Potential %
400.00 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     52.15
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     47.44
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
-1.35 
Earnings Rating
Neutral
Market Cap65.76M 
Earnings Date
21st Nov 2022
Alpha-0.01 Standard Deviation0.26
Beta1.10 

Today's Price Range

0.75000.8900

52W Range

0.86005.30

5 Year PE Ratio Range

-18.6011.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-12.13%
1 Month
-25.93%
3 Months
-38.46%
6 Months
-39.85%
1 Year
-82.48%
3 Years
-46.67%
5 Years
-93.15%
10 Years
-

TickerPriceChg.Chg.%
SMMT0.8000-0.0900-10.11
AAPL148.036.86004.86
GOOG101.456.01006.30
MSFT255.1414.81006.16
XOM111.340.80000.72
WFC47.950.38000.80
JNJ178.001.91001.08
FB196.640.99000.51
GE85.970.31000.36
JPM138.181.62001.19
 
ProfitabilityValueIndustryS&P 500US Markets
99.90
-8 247.60
-7 976.80
-
-
RevenueValueIndustryS&P 500US Markets
956.00K
0.01
-70.13
-
Earnings HistoryEstimateReportedSurprise %
Q03 2022--0.14-
Q02 2022--0.17-
Q01 2022--0.22-
Q04 2021--0.28-
Q03 2021-0.29-0.2031.03
Q02 2021-0.18-0.27-50.00
Q01 2021-0.17-0.21-23.53
Q04 2020-0.21-0.1814.29
Earnings Per EndEstimateRevision %Trend
12/2021 QR-0.273.57Positive
12/2021 FY-0.969.43Positive
3/2022 QR-0.280.00-
12/2022 FY-1.08-0.93Negative
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume454.47K
Shares Outstanding82.20K
Shares Float25.65M
Trades Count1.00K
Dollar Volume364.28K
Avg. Volume216.43K
Avg. Weekly Volume108.90K
Avg. Monthly Volume140.16K
Avg. Quarterly Volume400.21K

Summit Therapeutics Inc. (NASDAQ: SMMT) stock closed at 0.8 per share at the end of the most recent trading day (a -10.11% change compared to the prior day closing price) with a volume of 454.47K shares and market capitalization of 65.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 70 people. Summit Therapeutics Inc. CEO is Glyn Owain Edwards / Robert W. Duggan.

The one-year performance of Summit Therapeutics Inc. stock is -82.48%, while year-to-date (YTD) performance is -70.26%. SMMT stock has a five-year performance of -93.15%. Its 52-week range is between 0.86 and 5.3, which gives SMMT stock a 52-week price range ratio of -1.35%

Summit Therapeutics Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 1.42, a price-to-sale (PS) ratio of 80.83, a price to cashflow ratio of 23.50, a PEG ratio of 2.32, a ROA of -61.02%, a ROC of -71.69% and a ROE of -73.58%. The company’s profit margin is -%, its EBITDA margin is -7 976.80%, and its revenue ttm is $956.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Summit Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Summit Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Summit Therapeutics Inc. is (0), with a target price of $4, which is +400.00% compared to the current price. The earnings rating for Summit Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Summit Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Summit Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.63, ATR14 : 0.08, CCI20 : -186.80, Chaikin Money Flow : -0.32, MACD : -0.06, Money Flow Index : 37.66, ROC : -22.33, RSI : 30.68, STOCH (14,3) : 14.71, STOCH RSI : 0.00, UO : 40.56, Williams %R : -85.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Summit Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Hold
3.00

Summit Therapeutics Inc.

Summit Therapeutics Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of medicines for indications for which there inadequate or no therapies. It also conducts clinical programs focused on the genetic disease Cuchenne muscular dystrohy and the infectious disease Clostridium difficile infection. The company has drug development segment. All assets of the company are located in the United Kingdom.

CEO: Glyn Owain Edwards / Robert W. Duggan

Telephone: +1 617 514-7149

Address: One Broadway, Cambridge 02142, MA, US

Number of employees: 70

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

53%47%

Bearish Bullish

51%49%


News

Stocktwits